Shares of PTC Therapeutics, Inc. ( NASDAQ:PTCT – Get Free Report ) have been given a consensus recommendation of 'Hold' by the eleven ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have given a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $53.27. A number of brokerages recently commented on PTCT.

https://www.dailypolitical.com/2023/07/30/brokerages-set-ptc-therapeutics-inc-nasdaqptct-target-price-at-53-27.html

#dailypolitical